Table 6.

Published clinical studies on potential therapeutic agents in humans.

Topic of the Study	Aim of the Study	Number of Patients Included	Significant Findings, Safety, Disease Response, and Disease Control	Type of Study	Reference
Baclofen in AD treatment	To examine brain metabolites following administration of baclofen or placebo in AD individuals	31	There were significant differences between baclofen and placebo on parietal concentrations of glutathione when controlling for recent drinking, with baclofen-treated participants demonstrating significantly higher levels of GSH/Cr ratios relative to placebo	Randomized placebo-controlled trial	[138]
Influence of neonatal vitamin K and vulnerability to AD	To test the hypothesis that vitamin K supplementation administered to newborns facilitates the synthesis of blood-clotting proteins that might reduce the development of AD later in life	238	Vitamin K treatment was associated with significantly lower rates of AD and fewer symptoms of problem drinking	Retrospective cohort study	[151]
Tetrahydrobiopterin and microvascular dysfunction in young adult binge drinkers	To examine microvascular dysfunction in an ex vivo experimental model (isolated arterioles) from young adults with a history of repeated binge drinking, moderate alcohol drinking, and alcohol abstention and the role of tetrahydrobiopterin	36	In young adult binge drinkers, microvascular dysfunction may be exacerbated with acute pathophysiological stimulus; these binge-induced dysfunctions may be reversed by tetrahydrobiopterin	Cohort study	[150]

Alcohol dependence (AD).